Clinical Trial Update: HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a HER2-targeted molecular imaging agent, 68Ga-ABS011, for metastatic breast cancer is underway. The study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 68Ga-ABS011 (ABS011)

Snippet

Sponsor: Abscint NV/SA | Conditions: Metastatic Breast Cancer | Phase 2 | Status: RECRUITING